Osaic Holdings’s Travere Therapeutics TVTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$40.4K Sell
1,361
-6,518
-83% -$195K ﹤0.01% 5371
2025
Q4
$301K Buy
7,879
+7,758
+6,412% +$252K ﹤0.01% 3811
2025
Q3
$2.66K Buy
121
+68
+128% +$1.28K ﹤0.01% 7044
2025
Q2
$784 Buy
53
+30
+130% +$497 ﹤0.01% 7232
2025
Q1
$412 Sell
23
-54
-70% -$1.1K ﹤0.01% 7041
2024
Q4
$1.34K Sell
77
-47
-38% -$831 ﹤0.01% 6746
2024
Q3
$1.73K Hold
124
﹤0.01% 6671
2024
Q2
$1.02K Buy
124
+101
+439% +$680 ﹤0.01% 6810
2024
Q1
$177 Hold
23
﹤0.01% 6971
2023
Q4
$206 Hold
23
﹤0.01% 7038
2023
Q3
$205 Sell
23
-1,476
-98% -$20.8K ﹤0.01% 7151
2023
Q2
$23K Buy
1,499
+402
+37% +$7.31K ﹤0.01% 5469
2023
Q1
$24.7K Buy
1,097
+55
+5% +$1.17K ﹤0.01% 5447
2022
Q4
$21.1K Sell
1,042
-108
-9% -$2.29K ﹤0.01% 5520
2022
Q3
$29K Buy
1,150
+45
+4% +$1.16K ﹤0.01% 5327
2022
Q2
$27K Sell
1,105
-164
-13% -$4.12K ﹤0.01% 5410
2022
Q1
$33K Buy
1,269
+110
+9% +$2.92K ﹤0.01% 5389
2021
Q4
$36K Sell
1,159
-2
-0.2% -$56 ﹤0.01% 5393
2021
Q3
$28K Buy
1,161
+1,086
+1,448% +$20K ﹤0.01% 5538
2021
Q2
$1K Hold
75
﹤0.01% 6892
2021
Q1
$2K Hold
75
﹤0.01% 6526
2020
Q4
$2K Hold
75
﹤0.01% 6115
2020
Q3
$1K Hold
75
﹤0.01% 6082
2020
Q2
$2K Sell
75
-450
-86% -$7.17K ﹤0.01% 5832
2020
Q1
$8K Buy
+525
New +$7.9K ﹤0.01% 5144

Other funds holding TVTX

Osaic Holdings's TVTX Position: Q1 2026 in Review

Osaic Holdings reduced its Travere Therapeutics (TVTX) stake by 83% in Q1 2026, selling an estimated $195K and leaving 1,361 shares worth $40.4K. The position accounts for ﹤0.01% of the portfolio, ranked #5371.

Osaic Holdings first reported a position in TVTX in Q1 2020 and has held it in 25 quarters since. The position peaked at $301K in Q4 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Osaic Holdings held 1,361 shares of Travere Therapeutics worth $40.4K as of Q1 2026.
  • Osaic Holdings sold 6,518 Travere Therapeutics shares in Q1 2026, an estimated $195K.
  • Travere Therapeutics made up ﹤0.01% of Osaic Holdings's portfolio in Q1 2026, its #5371 holding.
  • Osaic Holdings first reported a position in Travere Therapeutics in Q1 2020 and has held it in 25 quarters since.
  • Osaic Holdings's Travere Therapeutics position peaked at $301K in Q4 2025.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Osaic Holdings's 13F filing for Q1 2026, filed 15 May 2026.